<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04813861</url>
  </required_header>
  <id_info>
    <org_study_id>2020-PI199-99</org_study_id>
    <nct_id>NCT04813861</nct_id>
  </id_info>
  <brief_title>Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation</brief_title>
  <acronym>CELPerCutCHC</acronym>
  <official_title>Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) can present itself in many forms (size, number of lesions) for&#xD;
      the treatment of which a therapeutic panel can be elaborated and layered. If a curative&#xD;
      treatment cannot be considered in case of an HCC classified in an intermediate stage, a&#xD;
      Transcatheter Arterial Chemoembolization (TACE) can be proposed. In case of a partial&#xD;
      response or the treatment of some lesions of a multifocal HCC, a combined treatment by&#xD;
      stereotaxic radiotherapy (CK), radiofrequency ablation (RFA) or microwave ablation (MWA) may&#xD;
      be initiated in accordance with a decision of the multidisciplinary consultation meeting.&#xD;
&#xD;
      The aim of this study was to evaluate the clinical outcome of HCC receiving MWA, RFA or CK&#xD;
      after downstaging with TACE.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2010</start_date>
  <completion_date type="Actual">March 2021</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion Response</measure>
    <time_frame>4-6 weeks after BWA or RFA or 3-6 months after CK</time_frame>
    <description>Lesion response after combined treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delayed Lesion Response</measure>
    <time_frame>1 year after BWA, RFA or CK</time_frame>
    <description>Lesion response a year after combined treatment</description>
  </secondary_outcome>
  <enrollment type="Actual">57</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have been treated for HCC by TACE, followed by additional treatment with RFA,&#xD;
        MWA or CK in the following year, between January 2010 and December 2020 by Nancy Regional&#xD;
        University Hospital (TACE, RFA, MWA) and Lorraine Institute of Cancer (CK)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  a HCC treated by TACE followed by RFA, MWA and/or CK&#xD;
&#xD;
          -  from 01/2010 to 12/2020&#xD;
&#xD;
          -  treated by Nancy Regional University Hospital (TACE, RFA, MWA) and Institut de&#xD;
             Cancérologie de Lorraine (CK)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Combined treatment over one year following the last TACE&#xD;
&#xD;
          -  No baseline, in between or after combined treatment imaging&#xD;
&#xD;
          -  Lesion appeared after TACE treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 21, 2021</study_first_submitted>
  <study_first_submitted_qc>March 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 21, 2021</last_update_submitted>
  <last_update_submitted_qc>March 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Valérie LAURENT</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Transarterial Chemoembolization</keyword>
  <keyword>Stereotactic body radiotherapy</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <keyword>Microwave Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

